237
Participants
Start Date
January 15, 2014
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2026
Osimertinib
It is administered orally everyday.
Nivolumab
It is an intravenous infusion administered every 14 days.
Telisotuzumab vedotin
It is administered by infusion in 21-day dosing cycles.
Telisotuzumab vedotin
It is administered by infusion in 28-day dosing cycles.
Erlotinib
It is administered orally everyday.
National Taiwan University Hospital /ID# 167173, Taipei City
National Cheng Kung University Hospital /ID# 167175, Tainan City
Universitair Ziekenhuis Antwerpen /ID# 170118, Edegem
Montefiore Medical Park at Eastchester /ID# 218445, The Bronx
Northwell Health - Monter Cancer Center /ID# 218170, Lake Success
Taipei Veterans General Hosp /ID# 217392, Taipei
AP-HM - Hopital de la Timone /ID# 151570, Marseille
Duplicate_The Catholic University of Korea, ST. Vincent's Hospital /ID# 233378, Suwon
Virginia Cancer Specialists - Fairfax /ID# 165708, Fairfax
Duplicate_Tampere University Hospital /ID# 165065, Tampere
Tennessee Oncology, PLLC /ID# 129802, Nashville
China Medical University Hospital /ID# 217494, Taichung
"Duplicate_Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRCCS /ID# 164077", Meldola
Duplicate_Henry Ford Health System /ID# 149857, Detroit
Herbert Herman Cancer Center /ID# 149858, Lansing
Ingalls Memorial Hosp /ID# 165876, Harvey
Washington University-School of Medicine /ID# 143798, St Louis
Mary Crowley Cancer Research /ID# 123760, Dallas
University of Texas MD Anderson Cancer Center /ID# 154648, Houston
Univ of Colorado Cancer Center /ID# 123759, Aurora
University of California, Los Angeles /ID# 148295, Los Angeles
City of Hope /ID# 153759, Duarte
UC Irvine /ID# 165107, Orange
Institut Gustave Roussy /ID# 132747, Villejuif
University of California, Davis Comprehensive Cancer Center /ID# 129805, Sacramento
Scottsdale Healthcare /ID# 123761, Scottsdale
The University of Chicago Medical Center /ID# 136995, Chicago
Massachusetts General Hospital /ID# 129804, Boston
Dana-Farber Cancer Institute /ID# 168782, Boston
Summit Medical Group-Florham Park /ID# 217651, Florham Park
Duke Cancer Center /ID# 123763, Durham
National Cancer Center Hospital East /ID# 217570, Kashiwa-shi
National Cancer Center Hospital /ID# 217571, Chuo-ku
Radboud Universitair Medisch Centrum /ID# 246908, Nijmegen
Asan Medical Center /ID# 217334, Seoul
Yonsei University Health System Severance Hospital /ID# 217333, Seoul
Lead Sponsor
AbbVie
INDUSTRY